CLXT News and Press, Calyxt Inc. From 11/03/22

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire — Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— — Continued to progress custom...

Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing PR Newswire -Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, r...

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time PR Newswire ROSEVILLE, Minn. , Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthe...

Calyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants PR Newswire ROSEVILLE, Minn. , Oct. 25, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology c...

Calyxt ( NASDAQ: CLXT ) said on Friday it had signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to develop and scale its proprietary Plant Cell Matrix (PCM) technology platform. Under the contract, Evologic will advance th...

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients PR Newswire Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutica...

Plant-based synthetic biology company Calyxt, Inc. ( NASDAQ: CLXT ) announced Thursday that it is exploring potential strategic alternatives to maximize shareholder value. CLXT shares added ~11% pre-market in reaction after a brief trading pause. As part of the pro...

Plant-based synthetic biology company Calyxt, Inc. ( NASDAQ: CLXT ) announced Thursday that the company is exploring potential strategic alternatives to maximize shareholder value. As part of the process, the CLXT board is weighing options, including the methods for financ...

Calyxt, Inc. Exploring Strategic Alternatives PR Newswire ROSEVILLE, Minn. , Sept. 22, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potentia...

Calyxt to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire ROSEVILLE, Minn. , Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michae...